{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Ta de Clinicagem","title":"TdC 357: Análogos de GLP-1 na prática - 4 clinicagens","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/877620a1\"></iframe>","width":"100%","height":180,"duration":2726,"description":"Marcela Belleza e Ênio Macedo convidam novamente Nathalie Santana para debater clinicagens sobre o uso dos análogos do peptídeo semelhante ao glucagon 1 (GLP-1) na prática. O episódio inicia explicando qual o panorama atual das medicações no Brasil (quais fármacos são comercializados, quebra de patente, como usar as canetas), e partem para as 4 clinicagens:\n- indicações além do tratamento da obesidade e do diabetes tipo 2\n- eventos adversos novos\n- cuidados em cenários específicos (gestações, perioperatório, idosos)\n- estratégias para suspensão e redução de custo  \nReferências:\nADA Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026.\nAronne LJ, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026.\nBatsis JA, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026.\nBliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024.\nBonaca MP, et al. Semaglutide and walking capacity in peripheral artery disease and type 2 diabetes (STRIDE). Lancet. 2025.\nCelletti F, et al. WHO guideline on GLP-1 therapies for obesity in adults. JAMA. 2026.\nDas SR, et al. 2020 ACC Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in type 2 diabetes. J Am Coll Cardiol. 2020.\nMarino EC, et al. Perioperative hyperglycemia screening and control: SBD/SBA/ABESO joint position statement. Brazilian Diabetes Society Guideline. 2026.\nHe L, et al. GLP-1 receptor agonists and risk of gallbladder and biliary diseases: a meta-analysis. JAMA Intern Med. 2022.\nHorn DB, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet. 2026.\nMalhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024.\nNauck MA, et al....","thumbnail_url":"https://img.transistorcdn.com/lqcQlEC1m6aWV5CJqKTqNKKWbLXziZKK97FisF4ZuuE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lODM1/ZmI0ODIxZjAxM2U1/ZGUwMjhkYTYwNzZi/MGNmNi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}